ARB1002 / Arbele - LARVOL DELTA

Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer (PRNewswire) - "ARB1002 is planned to enter a Phase 1 clinical trial this year, with Arbele completing IND-enabling studies to support its clinical evaluation in pancreatic cancer."

New P1 trial • Orphan drug • Pancreatic Cancer

ARB1002, a potential first-in-class CDH17-specific ADC, for treatment of pancreatic and other gastrointestinal cancers. (ASCO-GI 2026) - "The current 1L SOC is combination chemotherapy, most often FOLFIRINOX or gemcitabine plus nab-paclitaxel... ARB1002, promises to be a potential first-in-class/best-in-class ADC for treating advanced pancreatic cancers refractory to 1L gemcitabine chemotherapy."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CDH17 • CLDN18 • HER-2